A Double-Blind, Randomized, Placebo Controlled, Cross-Over, Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Volunteers

Trial Profile

A Double-Blind, Randomized, Placebo Controlled, Cross-Over, Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2012

At a glance

  • Drugs Dasolampanel (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2009 Results will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held 20-21 Nov 2009, according to a Raptor Pharmaceutical Corp media release.
    • 06 Jun 2008 New trial record.
    • 05 Jun 2008 Status changed from not yet recruiting to recruiting, reported in a TorreyPines media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top